300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Paraguay
Botswana
South Africa
Canada
Ireland
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
U.S. Venture Partners, VC Fund

U.S. Venture Partners

VC Fund

Menlo Park, United States

U.S. Venture Partners (USVP) is a venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the pastthirty-plus years of the firm's existence. Areas of particular interest to our investment professionals include enterprise software, IT security, consumer internet, mobile, and e-commerce, healthcare, and IT-enabled healthcare services. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals, and industry domain experts.

Total investments:
460
Last investment:
Lead investor:
33%
Fund size:
$400M
Last fund:

Last updated:

Industries U.S. Venture Partners invests in

SoftwareHealth CareInformation TechnologyMedicalManufacturing

Stages U.S. Venture Partners invests in

Series BSeries CSeries AFunding RoundSeries D

Countries U.S. Venture Partners invests in

United StatesIsraelCanadaFranceChina

Round sizes

Series A $5M–$40MSeries B $6.8M–$50MSeries C $7.8M–$68M

Contacts

NameEmailPhoneSocials
See all 9 contacts →

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$5M–$40M
Series B
$6.8M–$50M
Series C
$7.8M–$68M

Investment Focus

Industry

  • Software 61 (13%)
  • Health Care 51 (11%)
  • Information Technology 32 (7%)
  • Medical 28 (6%)
  • Manufacturing 27 (6%)
See all 213 industries →

Stage

  • Series B 100 (22%)
  • Series C 80 (17%)
  • Series A 71 (15%)
  • Funding Round 52 (11%)
  • Series D 35 (8%)
See all 12 stages →

Country

  • United States 197 (43%)
  • Israel 13 (3%)
  • Canada 3 (1%)
  • France 2 (0%)
  • China 1 (0%)
See all 6 countries →

Team

NameTitleInvestmentsLinksEmail
Phil Young
Phil Young Senior Advisor
Senior Advisor Total investments: 10
Find email
Casey Tansey
Casey Tansey General Partner
General Partner Total investments: 28 Find email
Dafina Toncheva
Dafina Toncheva General Partner
General Partner Total investments: 39
Find email
Dale Holladay
Dale Holladay CPA/CFO
CPA/CFO Total investments: 0
Find email
Jacques Benkoski
Jacques Benkoski General Partner
General Partner Total investments: 25
Find email
See all 9 team members →

Investments

CompanyDescriptionRoundLinks
Maneva develops video-to-action artificial intelligence systems for manufacturing environments, using computer vision and deep learning to analyze production processes and support operational decision-making in real time. Its platform helps manufacturers address quality assurance, downtime reduction, productivity monitoring, and workplace safety byconverting visual data from factory-floor cameras into actionable insights and automated responses. The company offers solutions such as VITA for defect detection, product verification, and equipment monitoring, as well as ALIS, an AI-powered line supervision system that tracks production efficiency and safety compliance. Maneva's technology is designed to work with existing camera infrastructure and can be applied across industries, including food and beverage, pharmaceuticals, electronics, automotive, steel, and distribution operations. The company focuses on helping manufacturers improve production consistency, identify operational issues, and monitor factory processes through AI-driven visual analysis. $27M / Series A / Jun 10, 2026
Cagent Vascular is a medical device company developing minimally invasive technologies to treat cardiovascular disease. $41M / Series D / May 19, 2026
Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system. Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. $52.5M / Series B / Apr 27, 2026
Route 92 Medical is a developer of a stealthy catheter for stroke treatment. The company was founded in 2015 and based in San Mateo, California. $50M / Private Equity / Apr 07, 2026
Slang.ai is a digital phone concierge that answers questions, takes reservations, and satisfies callers. $28M / Series B / Feb 24, 2026
Adaptive6 is a Cloud Cost Governance platform that addresses both cloud and code, providing a comprehensive approach to managing costs effectively. The platform empowers engineers to take immediate action on cloud costs and prevents waste at the code level, enhancing efficiency in cloud management. $28M / Series A / Jan 28, 2026
Okami Medical develops and commercializes new devices for the treatment of heart disease. It was formed to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive medical devices for the occlusion of peripheral vessels. Okami believes that vessel occlusion should be rapid and reliableregardless of tortuosity and flow conditions. The LOBO Vascular Occlusion System was developed for this reason.It was founded in 2011 and is headquartered in Aliso Viejo, California. $45M / Series F / Nov 19, 2025
Apono helps companies become secure and compliant while maintaining their productivity and agility. The company aims to simplify how teams manage access to critical systems by automating the provisioning and deprovisioning of permissions based on real-time needs, ensuring only the right people have access at the right time. $34M / Series B / Nov 18, 2025
Weave provides an artificial intelligence collaboration platform for biomedicine. The company is headquartered in the United States. $20M / Series A / Oct 16, 2025
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company addressing metabolic dysfunction from excess cortisol. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to deliver improved outcomes for patients who struggle to control diabetes and related metabolic conditions with currentoptions. Its lead product, clofutriben, is an oral, small molecule, designed to target the source of active intracellular cortisol in key tissues.The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States. $95M / Series B / Sep 24, 2025
See all 460 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Paraguay
Botswana
South Africa
Canada
Ireland
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does U.S. Venture Partners invest in?

U.S. Venture Partners invests primarily in Software, Health Care and Information Technology startups, most often at Series B and Series C stage. Most of the 460 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is U.S. Venture Partners's check size?

U.S. Venture Partners typically joins rounds of $5M–$40M at Series A, $6.8M–$50M at Series B and $7.8M–$68M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds U.S. Venture Partners participates in.

How do I contact U.S. Venture Partners?

Public channels for U.S. Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at U.S. Venture Partners?

The team at U.S. Venture Partners includes Phil Young (Senior Advisor), Casey Tansey (General Partner) and Dafina Toncheva (General Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
U.S. Venture Partners U.S. Venture Partners Find emails